New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires

Stock News

3小時前

The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.

According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.

The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1144335647"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144335647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144335647?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144335647","market":"other","top_or_hot":-1,"title":"New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires","media":"Stock News","content":"<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-07-27 07:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1144335647","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144335647","pubTimestamp":1785107898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REDS":"RPM Republican Senate ETF","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","KCE":"SPDR KBW Capital Markets ETF","FRHC":"Euronext CAC Health Care","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股"},"translate_title":"新股更新：康诺生物香港IPO招股说明书到期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REDS":1,"VXUS":1,"KCAI":1,"IPOS":1,"KCE":1,"FRHC":1},"content_text":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}